These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38689006)

  • 41. Catechol-O-methyltransferase Val158Met polymorphism: modulation of wearing-off susceptibility in a Chinese cohort of Parkinson's disease.
    Wu H; Dong F; Wang Y; Xiao Q; Yang Q; Zhao J; Quinn TJ; Chen SD; Liu J
    Parkinsonism Relat Disord; 2014 Oct; 20(10):1094-6. PubMed ID: 25108642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of common genetic variants in cognitive decline in the first seven years of Parkinson's disease: A longitudinal observational study.
    Chung J; Ushakova A; Doitsidou M; Tzoulis C; Tysnes OB; Dalen I; Pedersen KF; Alves G; Maple-Grødem J
    Neurosci Lett; 2021 Nov; 764():136243. PubMed ID: 34509566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Motor symptoms in Parkinson's disease are related to the interplay between cortical curvature and thickness.
    Almgren H; Hanganu A; Camacho M; Kibreab M; Camicioli R; Ismail Z; Forkert ND; Monchi O
    Neuroimage Clin; 2023; 37():103300. PubMed ID: 36580712
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease.
    Caspell-Garcia C; Simuni T; Tosun-Turgut D; Wu IW; Zhang Y; Nalls M; Singleton A; Shaw LA; Kang JH; Trojanowski JQ; Siderowf A; Coffey C; Lasch S; Aarsland D; Burn D; Chahine LM; Espay AJ; Foster ED; Hawkins KA; Litvan I; Richard I; Weintraub D;
    PLoS One; 2017; 12(5):e0175674. PubMed ID: 28520803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease.
    Filippi M; Canu E; Donzuso G; Stojkovic T; Basaia S; Stankovic I; Tomic A; Markovic V; Petrovic I; Stefanova E; Kostic VS; Agosta F
    Mov Disord; 2020 Nov; 35(11):1987-1998. PubMed ID: 32886420
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of COMT H108L, MAOB int 13 A>G and DRD2 haplotype on the susceptibility to Parkinson's disease in South Indian subjects.
    Kumudini N; Umai A; Devi YP; Naushad SM; Mridula R; Borgohain R; Kutala VK
    Indian J Biochem Biophys; 2013 Oct; 50(5):436-41. PubMed ID: 24772965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Effects of COMT Polymorphism on Cortical Thickness and Surface Area Abnormalities in Children with ADHD.
    Jung M; Mizuno Y; Fujisawa TX; Takiguchi S; Kong J; Kosaka H; Tomoda A
    Cereb Cortex; 2019 Aug; 29(9):3902-3911. PubMed ID: 30508034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
    Michałowska M; Chalimoniuk M; Jówko E; Przybylska I; Langfort J; Toczylowska B; Krygowska-Wajs A; Fiszer U
    Brain Behav; 2020 Mar; 10(3):e01537. PubMed ID: 32022467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality.
    Danti S; Toschi N; Diciotti S; Tessa C; Poletti M; Del Dotto P; Lucetti C
    Eur J Neurol; 2015 Dec; 22(12):1564-72. PubMed ID: 26212370
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cortical Implications of Advancing Age and Disease Duration in Parkinson's Disease Patients with Postural Instability and Gait Dysfunction.
    Herb JN; Rane S; Isaacs DA; Van Wouwe N; Roman OC; Landman BA; Dawant BM; Hedera P; Zald DH; Neimat JS; Wylie SA; Donahue MJ; Claassen DO
    J Parkinsons Dis; 2016 May; 6(2):441-51. PubMed ID: 27164041
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
    Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
    Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patterns of cortical thinning in nondemented Parkinson's disease patients.
    Uribe C; Segura B; Baggio HC; Abos A; Marti MJ; Valldeoriola F; Compta Y; Bargallo N; Junque C
    Mov Disord; 2016 May; 31(5):699-708. PubMed ID: 27094093
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Longitudinal brain atrophy distribution in advanced Parkinson's disease: What makes the difference in "cognitive status" converters?
    Gorges M; Kunz MS; Müller HP; Liepelt-Scarfone I; Storch A; Dodel R; Hilker-Roggendorf R; ; Berg D; Kalbe E; Braak H; Del Tredici K; Baudrexel S; Huppertz HJ; Kassubek J
    Hum Brain Mapp; 2020 Apr; 41(6):1416-1434. PubMed ID: 31789477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism.
    Klebe S; Golmard JL; Nalls MA; Saad M; Singleton AB; Bras JM; Hardy J; Simon-Sanchez J; Heutink P; Kuhlenbäumer G; Charfi R; Klein C; Hagenah J; Gasser T; Wurster I; Lesage S; Lorenz D; Deuschl G; Durif F; Pollak P; Damier P; Tison F; Durr A; Amouyel P; Lambert JC; Tzourio C; Maubaret C; Charbonnier-Beaupel F; Tahiri K; Vidailhet M; Martinez M; Brice A; Corvol JC; ;
    J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):666-73. PubMed ID: 23408064
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese population.
    Kiyohara C; Miyake Y; Koyanagi M; Fujimoto T; Shirasawa S; Tanaka K; Fukushima W; Sasaki S; Tsuboi Y; Yamada T; Oeda T; Shimada H; Kawamura N; Sakae N; Fukuyama H; Hirota Y; Nagai M;
    BMC Neurol; 2011 Jul; 11():89. PubMed ID: 21781348
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Imaging and genetics in Parkinson's disease: assessment of the GBA1 mutation.
    Ghatti S; Yoon E; Lopez G; Ehrlich D; Horovitz SG
    J Neurol; 2022 Oct; 269(10):5347-5355. PubMed ID: 35604467
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The COMT Val158Met polymorphism as an associated risk factor for Parkinson's disease in Asian rather than Caucasian populations.
    Lechun L; Yu S; Pengling H; Changqi H
    Neurol India; 2013; 61(1):12-6. PubMed ID: 23466833
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regional Cerebral Cortical Atrophy is Related to Urinary Tract Symptoms in Parkinson's Disease.
    Roh H; Kang J; Hwang SY; Koh SB; Kim JH
    J Neuroimaging; 2021 Mar; 31(2):363-371. PubMed ID: 33534966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gender-based analysis of cortical thickness and structural connectivity in Parkinson's disease.
    Yadav SK; Kathiresan N; Mohan S; Vasileiou G; Singh A; Kaura D; Melhem ER; Gupta RK; Wang E; Marincola FM; Borthakur A; Haris M
    J Neurol; 2016 Nov; 263(11):2308-2318. PubMed ID: 27544505
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations.
    Camicioli R; Rajput A; Rajput M; Reece C; Payami H; Hao C; Rajput A
    Mov Disord; 2005 Aug; 20(8):989-94. PubMed ID: 15852364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.